Brokerages Set ABIVAX Société Anonyme (NASDAQ:ABVX) PT at $38.67

ABIVAX Société Anonyme (NASDAQ:ABVX) has been given an average rating of “Buy” by the seven research firms that are currently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating on the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $38.67.

Several research firms have recently issued reports on ABVX. Citizens Jmp raised ABIVAX Société Anonyme to a “strong-buy” rating in a research note on Wednesday, December 4th. JMP Securities reissued a “market outperform” rating and set a $33.00 target price on shares of ABIVAX Société Anonyme in a report on Friday, January 10th.

Institutional Trading of ABIVAX Société Anonyme

Several institutional investors have recently added to or reduced their stakes in the stock. ADAR1 Capital Management LLC lifted its position in shares of ABIVAX Société Anonyme by 190.1% in the 4th quarter. ADAR1 Capital Management LLC now owns 1,513,393 shares of the company’s stock worth $11,078,000 after purchasing an additional 991,781 shares during the period. Caligan Partners LP bought a new position in ABIVAX Société Anonyme during the fourth quarter worth $5,506,000. JPMorgan Chase & Co. bought a new position in ABIVAX Société Anonyme during the fourth quarter worth $5,336,000. Allostery Investments LP acquired a new position in ABIVAX Société Anonyme in the fourth quarter valued at $4,328,000. Finally, Nantahala Capital Management LLC boosted its position in ABIVAX Société Anonyme by 45.7% during the fourth quarter. Nantahala Capital Management LLC now owns 1,436,047 shares of the company’s stock valued at $10,512,000 after acquiring an additional 450,413 shares during the last quarter. 47.91% of the stock is currently owned by institutional investors.

ABIVAX Société Anonyme Stock Performance

Shares of ABVX stock opened at $6.80 on Friday. ABIVAX Société Anonyme has a twelve month low of $5.50 and a twelve month high of $17.02. The stock’s fifty day simple moving average is $6.69 and its 200 day simple moving average is $8.61.

ABIVAX Société Anonyme Company Profile

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.